Abstract
Cognitive impairments are common in severe mental illnesses (SMI), such as schizophrenia (SZ) and bipolar (BD) spectrum disorders, with substantial heterogeneity in both diagnostic categories. It has been suggested that dysregulation of immune and inflammatory pathways may contribute to cognitive impairment. This study aimed to investigate covariance patterns between cognitive domains and inflammatory/immune-related markers and further elucidate inter-individual variance in a large SMI and healthy control (HC) cohort (SZ = 343, BD = 298, HC = 770). We applied canonical correlation analysis (CCA) to identify modes of maximum covariation between a comprehensive selection of cognitive measures and inflammatory/immune markers. We found that poor verbal learning and psychomotor processing speed was associated with higher levels of interleukin-18 system cytokines and beta defensin 2, reflecting enhanced activation of innate immunity, a pattern augmented in SMI compared to HC. Applying hierarchical clustering on covariance patterns identified by the CCA revealed a high cognition – low immune dysregulation subgroup with predominantly HC (24% SZ, 45% BD, 74% HC) and a low cognition – high immune dysregulation subgroup predominantly consisting of SMI patients (76% SZ, 55% BD, 26% HC). These subgroups differed in IQ, years of education, age, CRP, BMI (all groups), level of functioning, symptoms and DDD of antipsychotics (SMI cohort). Our findings suggest a potential link between cognitive functioning and innate immune dysregulation.
Competing Interest Statement
OOA is a consultant to HealthLytix. Remaining authors have no conflicts of interest to declare.
Funding Statement
This study was funded by the South-Eastern Norway Regional Health Authority (grant number 2020089) and Research Council of Norway (#223273).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Regional Ethics Committee (REK) of South-East Norway gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data are not publicly available due to privacy and ethical restrictions.
